© Reuters. A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
(Reuters) – Pfizer (NYSE:) and German partner BioNTech (NASDAQ:) said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against the virus strains in early- to mid-stage trials.
The companies said they plan to start a late-stage trial in the coming months.